سوق علاج السرطان - النمو والاتجاهات وتأثير COVID-19 والتوقعات (2023 - 2028)

Table of Contents

1. 1. INTRODUCTION

   1. 1.1 Study Assumptions and Market Definition

   2. 1.2 Scope of the Study

2. 2. RESEARCH METHODOLOGY

3. 3. EXECUTIVE SUMMARY

4. 4. MARKET DYNAMICS

   1. 4.1 Market Overview

   2. 4.2 Market Drivers

      1. 4.2.1 Increasing Patient Assistance Programs (PAPs) and Rising Demand for Personalized Medicine

      2. 4.2.2 Growing Government Initiatives for Cancer Awareness

      3. 4.2.3 Rising Prevalence of Cancer Worldwide

      4. 4.2.4 Strong R&D Initiatives from Key Players

   3. 4.3 Market Restraints

      1. 4.3.1 Fluctuation in Reimbursement Policies

      2. 4.3.2 High Cost of Cancer Therapies

   4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

5. 5. MARKET SEGMENTATION

   1. 5.1 Therapy Type

      1. 5.1.1 Chemotherapy

      2. 5.1.2 Targeted Therapy

      3. 5.1.3 Immunotherapy

      4. 5.1.4 Hormonal Therapy

      5. 5.1.5 Other Treatment Types

   2. 5.2 Cancer Type

      1. 5.2.1 Blood Cancer

      2. 5.2.2 Breast Cancer

      3. 5.2.3 Prostate Cancer

      4. 5.2.4 Gastrointestinal Cancer

      5. 5.2.5 Gynaecologic Cancer

      6. 5.2.6 Respiratory/Lung Cancer

      7. 5.2.7 Other Cancer Types

   3. 5.3 End User

      1. 5.3.1 Hospitals

      2. 5.3.2 Specialty Clinics

      3. 5.3.3 Cancer and Radiation Therapy Centers

   4. 5.4 Geography

      1. 5.4.1 North America

         1. 5.4.1.1 United States (By Therapy Type, By Cancer Type, and By End User)

         2. 5.4.1.2 Canada (By Therapy Type, By Cancer Type, and By End User)

         3. 5.4.1.3 Mexico (By Therapy Type, By Cancer Type, and By End User)

      2. 5.4.2 Europe

         1. 5.4.2.1 Germany (By Therapy Type, By Cancer Type, and By End User)

         2. 5.4.2.2 United Kingdom (By Therapy Type, By Cancer Type, and By End User)

         3. 5.4.2.3 France (By Therapy Type, By Cancer Type, and By End User)

         4. 5.4.2.4 Italy (By Therapy Type, By Cancer Type, and By End User)

         5. 5.4.2.5 Spain (By Therapy Type, By Cancer Type, and By End User)

         6. 5.4.2.6 Rest of Europe (By Therapy Type, By Cancer Type, and By End User)

      3. 5.4.3 Asia-Pacific

         1. 5.4.3.1 China (By Therapy Type, By Cancer Type, and By End User)

         2. 5.4.3.2 Japan (By Therapy Type, By Cancer Type, and By End User)

         3. 5.4.3.3 India (By Therapy Type, By Cancer Type, and By End User)

         4. 5.4.3.4 Australia (By Therapy Type, By Cancer Type, and By End User)

         5. 5.4.3.5 South Korea (By Therapy Type, By Cancer Type, and By End User)

         6. 5.4.3.6 Rest of Asia-Pacific (By Therapy Type, By Cancer Type, and By End User)

      4. 5.4.4 Middle-East and Africa

         1. 5.4.4.1 GCC (By Therapy Type, By Cancer Type, and By End User)

         2. 5.4.4.2 South Africa (By Therapy Type, By Cancer Type, and By End User)

         3. 5.4.4.3 Rest of Middle-East and Africa (By Therapy Type, By Cancer Type, and By End User)

      5. 5.4.5 South America

         1. 5.4.5.1 Brazil (By Therapy Type, By Cancer Type, and By End User)

         2. 5.4.5.2 Argentina (By Therapy Type, By Cancer Type, and By End User)

         3. 5.4.5.3 Rest of South America (By Therapy Type, By Cancer Type, and By End User)

6. 6. COMPETITIVE LANDSCAPE

   1. 6.1 Company Profiles

      1. 6.1.1 Amgen Inc.

      2. 6.1.2 Astrazeneca PLC

      3. 6.1.3 Bayer AG

      4. 6.1.4 Johnson and Johnson

      5. 6.1.5 Merck & Co. Inc.

      6. 6.1.6 F.Hoffmann-La Roche AG

      7. 6.1.7 Eli Lilly and Company

      8. 6.1.8 Novartis AG

      9. 6.1.9 Pfizer Inc.

      10. 6.1.10 Abbvie Inc.

      11. 6.1.11 Astellas Pharma Inc.

      12. 6.1.12 Celgene Corporation

      13. 6.1.13 GlaxoSmithKline PLC

      14. 6.1.14 Takeda Pharmaceutical Company Ltd

      15. 6.1.15 Bristol Myers Squibb Company

      16. 6.1.16 Gilead Sciences Inc. (Kite Pharma)

      17. 6.1.17 Ziopharm Oncology Inc.

      18. 6.1.18 Celldex Therapeutics Inc.

   *List Not Exhaustive

7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS